The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Update: Category 2 Removals Explained FDA UPDATED PEPTIDES APRIL 15, 2026 Most people are already getting this wrong. Today, the FDA updated its 503A compounding categories and removed several peptides from the high risk (Category 2) HIMS: Regulatory Arbitrage and the Future of Personalized Medicine